Clinical Trials Logo

Fasting Plasma Glucose clinical trials

View clinical trials related to Fasting Plasma Glucose.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06239506 Recruiting - Type 2 Diabetes Clinical Trials

Novel Brominated and Organophosphate Flame Retardants and Type 2 Diabetes

Start date: January 1, 2022
Phase:
Study type: Observational

As alternative flame retardants (FRs), novel brominated flame retardants (NBFRs) and organophosphate flame retardants (OPFRs) are ubiquitous in environment and may cause endocrine disruption effects. The associations between traditional endocrine-disrupting chemicals (EDCs) and type 2 diabetes have been extensively reported in epidemiological studies. To date, however, human-based evidence on the effects of NBFRs and OPFRs is lacking. The investigators conducted a case-control study of 344 participants aged 25-80 years from Shandong Province, East China, to assess potential associations between serum NBFR and OPFR concentrations and etiology of type 2 diabetes for the first time.

NCT ID: NCT03206593 Recruiting - Clinical trials for Ischemic Heart Failure

Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure

Start date: January 1, 2016
Phase: N/A
Study type: Observational [Patient Registry]

Current prospective cohort study is to evaluate the association between fasting lipid profiles (including total cholesterol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, triglycerides, apolipoprotein A, apolipoprotein B and lipoprotein(a)) and fasting plasma glucose at admission with cardiovascular disease outcomes (including fatal and non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, re-hospitalization due to heart failure, revascularization by percutaneous coronary intervention or coronary artery bypass grafting, or cardiovascular mortality) and all-cause mortality.in patients with ischemic heart failure and left ventricular ejection fraction < 45 % evaluated by echocardiography during 12 months follow-up.